Navigation Links
US study shows that tofacitinib is an efficacious treatment for active RA
Date:5/25/2011

Results of a Phase III study presented today at the EULAR 2011 Annual Congress show that at 6 months, 58.3 percent of patients who had previously not responded to treatment with DMARDs, achieved ACR20 response (a 20 percent improvement in symptoms) when treated with the novel oral Janus kinase inhibitor tofacitinib at 10mg BID compared to 31.2 percent in the placebo group. Significant improvements were also observed in the 5 mg BID dose.

Most adverse events were mild and no new safety signals were reported, according to study authors.

Results of the 12 month multinational study, conducted with 792 patients also show that 36.6% and 16.2% of patients achieved ACR50 and ACR70 responses respectively in the 10mg BID group, a significant improvement in symptoms compared to placebo, where 31.2%, 12.7% and 3.2% of patients achieved ACR 20, 50 and 70 respectively. Significant improvements in the Disease Activity Score physician index (DAS28***) were also observed in the treatment groups compared to placebo, along with improvements in the Health Assessment Questionnaire**** (HAQ) compared to placebo.

"We know that JAK plays a fundamental role in the signalling pathways that regulate RA and interrupting the uncontrolled inflammatory cascades seen in this study provides a novel way of modifying the progression of the disease said Professor Joel Kremer of the Albany Medical College in Albany USA. "Tofacitinib appears to reduce the signs and symptoms of RA very rapidly, and we hope that after carefully considering the benefit/risk equation that this compound will provide an additional valuable treatment option for patients who have experienced an inadequate response to prior treatments."

According to researchers, significant ACR 20, ACR50 and ACR70 responses were seen after 2 weeks of therapy (results not published). Patients received concurrent non-biologic background therapy with DMARDs (including methotrexate, leflunomide, sulfasalazine, hydroxychloroquine, penicillamine and gold, both as single agents and as combination therapies). 81.4% of the 792 patients studied were female, with ages ranging between 50.8-53.3 years. Whilst the majority of adverse events reported were mild (infections and infestations), four deaths were reported in the 5 mg and 10mg BID arms. Four opportunistic infections were also reported.

Results of a separate study shows promising results in several patient subgroups

Results of a further, multinational Phase III tofacitinib study (SAT0243) of 610 patients analysing selected subgroups in the USA have shown that clinically significant efficacy and safety was demonstrated in a number of subgroups investigated, including age, weight, prior DMARD status and the presence of RF / anti-CCP antibodies. Of note, patients who were younger (those aged up to 65 years), slimmer (those weighing less than 50kg), those testing positive to anti-CCP and negative to Rheumatoid Factor showed an improved response to 5mg or 10mg tofacitinib compared to placebo.


'/>"/>

Contact: Rory Berrie
rory.berrie@cohnwolfe.com
44-790-151-3297
European League Against Rheumatism
Source:Eurekalert

Related medicine news :

1. Study finds much different work histories for disability rejects, beneficiaries
2. Study Ties Blood Markers to Death Risk in Heart Failure
3. Temple-led study finds widening gap between distracted driving and legislation
4. Brisk walking may help men with prostate cancer, UCSF study finds
5. New study aims to improve long-term treatment for patients with bipolar disorder
6. Medicare improved Canadian doctors salaries: Queens University study
7. IUPUI study first to look at early treatment of depression to reduce heart disease risk
8. A Cultured Man Is a Healthier, Happier Man: Study
9. New study finds that violence doesnt add to childrens enjoyment of TV shows, movies
10. UTMB researcher receives $3 million NIH grant to study aging in Mexico
11. Study finds patient navigation increases colorectal cancer screening in ethnically diverse patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop ... The fitness app plans to fix the two major problems leading the fitness industry today:, ... all type program , They don’t eliminate all the reasons people quit their ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology: